Evidence map›Paper›PMID 36606762›Full record

ArticleLab on a chip2023

Multiplexed analysis of signalling proteins at the single-immune cell level.

Claudius L Dietsche, Elisabeth Hirth, Petra S Dittrich

Open access · hybridAbstract read
In one paragraph

Article in Lab on a chip, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Claudius L DietscheDepartment of Biosystems and Engineering, ETH Zurich, Mattenstrasse 26, 4125 Basel, Switzerland. petra.dittrich@bsse.ethz.ch.ORCID 0000-0003-3732-6971
Elisabeth HirthDepartment of Biosystems and Engineering, ETH Zurich, Mattenstrasse 26, 4125 Basel, Switzerland. petra.dittrich@bsse.ethz.ch.
Petra S DittrichDepartment of Biosystems and Engineering, ETH Zurich, Mattenstrasse 26, 4125 Basel, Switzerland. petra.dittrich@bsse.ethz.ch.ORCID 0000-0001-5359-8403
ETH Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High numbers of tumour-associated macrophages (TAMs) in the tumour microenvironment are associated with a poor prognosis. However, the effect of TAMs on tumour progression depends on the proteins secreted by individual TAMs. Here, we developed a microfluidic platform to quantitatively measure the secreted proteins of individual macrophages as well as macrophages polarized by the culture medium derived from breast cancer cells. The macrophages were captured in hydrodynamic traps and isolated with pneumatically activated valves for single-cell analysis. Barcoded and functionalized magnetic beads were captured in specially designed traps to determine the secreted proteins by immunoassay. Individual bead trapping facilitated the recording of the protein concentration since all beads were geometrically constrained in the same focal plane, which is an important requirement for rapid and automated image analysis. By determining three signaling proteins, namely interleuking 10 (IL-10), vascular endothelial growth factor (VEGF), and tumour necrosis factor alpha (TNF-α), we successfully distinguished between differently polarized macrophages. The results indicate a heterogeneous pattern, with M2 macrophages characterized by a higher secretion of IL-10, while M1 macrophages secrete high levels of the inflammatory cytokine TNF-α. The macrophages treated with the supernatant from cancer cells show a similar signalling pattern to M2 macrophages with an increased secretion of the pro-tumoural cytokine VEGF. This microfluidic method resolves correlations in signaling protein expression at the single-cell level. Ultimately, single-macrophage analysis can contribute to the development of novel therapies aimed at reversing M2-like TAMs into M1-like TAMs.

Indexed as

Interleukin-10Vascular Endothelial Growth Factor ACell Line, TumorCytokinesMacrophagesTumor MicroenvironmentTumor Necrosis Factor-alphaCytokinesInterleukin-10Tumor Necrosis Factor-alphaVascular Endothelial Growth Factor A

Identifiers

PMID36606762
PMCPMC9844122
OpenAlexW4311747008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.